GTC Biotherapeutics (fka GTCB)

[keitern]

>>Background on rhFVIIa

The total worldwide sales of the current recombinant factor VIIa product in all indications were reported to be $845 million (US) in 2005. An independent market research report estimates the worldwide sales of rhFVIIa will reach $2 billion (US) by 2012. Both plasma-derived and recombinant products are used in treating hemophilia caused by genetic conditions in which patients' failure to express enough coagulation factors on their own may lead to excessive bleeding. The application of transgenic technology may enable the production and pricing of rhFVIIa at appropriate levels for broader utilization of rhFVIIa, as well as expanding its use to the treatment of the unmet needs of patients in developing countries and to the treatment of other acquired bleeding conditions.

RhFVIIa will be developed from the milk of transgenic rabbits. Rabbits are anticipated to be capable of supplying the projected needs of the marketplace.<<

I would appreciate an in depth discussion on rhFVIIa. The language of the above paragraph is just enough to raise a ton of questions, for me anyway. What is the "current recombinant factor VIIa product" and who makes it? How do we just step in and "enable the production and pricing of rhFVIIa at appropriate levels for broader utilization"? What does that mean?